Company Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia.
Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.
The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1992 |
| IPO Date | May 23, 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,800 |
| CEO | Kyle Gano |
Contact Details
Address: 12780 El Camino Real San Diego, California 92130 United States | |
| Phone | 858 617 7600 |
| Website | neurocrine.com |
Stock Details
| Ticker Symbol | NBIX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000914475 |
| CUSIP Number | 64125C109 |
| ISIN Number | US64125C1099 |
| Employer ID | 33-0525145 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kyle W. Gano Ph.D. | Chief Executive Officer and Director |
| Matthew C. Abernethy CPA | Chief Financial Officer |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer |
| Eric S. Benevich | Chief Commercial Officer |
| Dr. Eiry Wyn Roberts M.D. | Strategic Advisor |
| Dr. Wylie W. Vale Ph.D. | Co-Founder |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder of Neurocrine |
| Lewis Choi | Chief Information Officer |
| Jane Sorensen | Head of Investor Relations |
| Darin M. Lippoldt Esq. | Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | 144 | Filing |
| Jul 30, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 10, 2025 | 144 | Filing |
| Jul 2, 2025 | 144 | Filing |
| May 30, 2025 | 8-K | Current Report |
| May 27, 2025 | 144 | Filing |
| May 22, 2025 | 8-K | Current Report |
| May 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |